Sheet

Substitute for form 1449A/PTO

| 기 + 1 | 1 | + | |
|-------|---|---|--|
|-------|---|---|--|

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) of

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Complete if Known | | | | |
|------------------------|--------------------------------|--|--|--|
| Application Number | PCT/US01/09265 | | | |
| Filing Date | | | | |
| First Named Inventor | Rebecca Guggemos Bakker-Arkema | | | |
| Group Art Unit | | | | |
| Examiner Name | | | | |
| Attorney Docket Number | A0000343-01-CA | | | |

U.S. PATENT DOCUMENTS umns, Lines, U.S. Patent Document Date of Publication of Name of Patentee or Applicant Ch re Relevant Cited Document Kind Code Passages or Relevant of Cited Document Initials* No. MM-DD-YYYY Figures Appear

| | | | | FORE | GN PATENT DOCUMENTS | S | | |
|----------------------|--------------|---------------------|---------------------|-------------------------------|--|--|--|-----------|
| Examiner Initials | Cite No.1 | Office ³ | Number ⁴ | Ocument Kind Codes (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines. Where Relevant Passages or Relevant Figures Appear | 7 |
| | | / | | | | | | \perp |
| | | 4 | | | | | | + |
| | - / | | | | | \ | | ╁ |
| | /- | | | | | | | I |
| | | | | | | | | 1 |
| / | | | | | | \ | | ╀ |
| -/- | - | | | | | | | \dagger |
| / | | 122 | | | | | | |

Date Examiner Considered Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant. 1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTC/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Curborities | te for form 1449B/P | 1449B/PTO | | Complete if Known | | |
|-----------------------------------|---------------------|-----------|-----------|------------------------|--------------------------------|--|
| INFORMATION DISCLOSURE | | | | Application Number | PCT/US01/09265 | |
| | | | | Filing Date | | |
| STATEMENT BY APPLICANT | | | APPLICANT | First Named Inventor | Rebecca Guggemos Bakker-Arkema | |
| (use as many sheets as necessary) | | | | Group Art Unit | | |
| | | | | Examiner Name | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | A0000343-01-CA | |

| Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the term (book, magazine, journal, serial, symposium, catalog, atc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. PCT International Search Report, PCT/US01/09265 (2002) CHAN, et al, "VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist Advances in Experimental Medicine and Biology, Vol. 449, 1998 pp 439-443 SWAN, et al, "Interaction between VPA-985, an ADH (V2) antagonist and furosemide", Journal of the American Society of Nephrology, Vol. 10, 1999, pp 124A TANEJA, et al, "Current status of acute intravenous therapy for chronic heart failure exacerbations", Congestive Heart Failure, Vol. 5, No. 5, 1999, pp 199-207, 215 | |
|--|-----|
| CHAN, et al, "VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist Advances in Experimental Medicine and Biology, Vol. 449, 1998 pp 439-443 SWAN, et al, "Interaction between VPA-985, an ADH (V2) antagonist and furosemide", Journal of t American Society of Nephrology, Vol. 10, 1999, pp 124A TANEJA, et al, "Current status of acute intravenous therapy for chronic heart failure exacerbations". | T2 |
| Advances in Experimental Medicine and Biology, Vol. 449, 1998 pp 439-443 SWAN, et al, "Interaction between VPA-985, an ADH (V2) antagonist and furosemide", Journal of t American Society of Nephrology, Vol. 10, 1999, pp 124A TANEJA, et al, "Current status of acute intravenous therapy for chronic heart failure exacerbations", | |
| American Society of Nephrology, Vol. 10, 1999, pp 124A TANEJA, et al, "Current status of acute intravenous therapy for chronic heart failure exacerbations". | n , |
| TANEJA, et al, "Current status of acute intravenous therapy for chronic heart failure exacerbations", Congestive Heart Failure, Vol. 5, No. 5, 1999, pp 199-207, 215 | he |
| | |
| · | · |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not distion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.